Aileron Therapeutics (ALRN)
(Delayed Data from NSDQ)
$2.75 USD
-0.02 (-0.72%)
Updated Jul 23, 2024 04:00 PM ET
After-Market: $2.75 0.00 (0.00%) 7:08 PM ET
3-Hold of 5 3
D Value F Growth F Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ALRN 2.75 -0.02(-0.72%)
Will ALRN be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ALRN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ALRN
Are Medical Stocks Lagging Sensus Healthcare (SRTS) This Year?
Down -36.29% in 4 Weeks, Here's Why Aileron Therapeutics (ALRN) Looks Ripe for a Turnaround
ALRN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Bears are Losing Control Over Aileron Therapeutics, Inc. (ALRN), Here's Why It's a 'Buy' Now
Aileron Therapeutics, Inc. (ALRN) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
What Makes Aileron Therapeutics, Inc. (ALRN) a New Buy Stock
Other News for ALRN
Aileron Therapeutics initiated with bullish view at Brookline
Aileron Therapeutics Announces New Interim CFO Appointment
Aileron Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
ALRN Stock Earnings: Aileron Therapeutics Reported Results for Q1 2024
Aileron Therapeutics GAAP EPS of -$0.86 beats by $0.16